Newswise — As the fourth most commonly diagnosed cancer among women worldwide, cervical cancer places a significant burden on low and middle-income countries. Although China reports lower incidence and mortality rates compared to the global average, the stark contrast in mortality rates with developed nations like the USA and the UK underscores the urgent need for enhanced prevention strategies. A new perspective (DOI:10.
20892/j.issn.2095-3941.
2023.0432 ) published in Cancer Biology & Medicine , March 2024, provides an in-depth look at the escalating rates of cervical cancer in China, particularly highlighting the rise in rural areas. This critical research emphasizes the effectiveness of the HPV vaccine in combatting cervical cancer and addresses challenges such as vaccine supply constraints, socioeconomic barriers, and vaccine hesitancy.
Researchers analyzed data reflecting the effectiveness of the HPV vaccine, which has proven to be a critical tool in reducing cancer rates. However, the introduction of the vaccine in China was delayed compared to other countries, affecting overall vaccination coverage. The study also evaluates the impact of China's adoption of the WHO’s “90-70-90” strategy—aiming for high vaccination, screening, and treatment rates by 2030.
The research outlines the urgent need for a multi-faceted approach that includes boosting vaccine supply, expanding screening programs, and enhancing treatment facilities to address the geographic and economic.
